HHS Public Access

Author manuscript

Immunity. Author manuscript; available in PMC 2023 January 30.

Published in final edited form as:

Immunity. 2022 November 08; 55(11): 2206–2208. doi:10.1016/j.immuni.2022.09.015.

Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing

Brendan W. MacNabb,

Xiufen Chen,

Sravya Tumuluru,

James Godfrey,

Darshan N. Kasal,

Jovian Yu,

Marlieke L.M. Jongsma,

Robbert M. Spaapen,

Douglas E. Kline,

Justin Kline*

During figure reformatting late in the publication process, the flow cytometry plots shown in Figure 2F were inadvertently duplicated such that those showing production of IFN-γ by restimulated 2C T cells (top row of Figure 2F) were copied and mistakenly displayed for TNF-α (middle row) and Granzyme B (bottom row). The plots have been reverted to display the correct flow cytometry plots. Additionally, the name order for the authors has been updated to reflect contributions to the work during the revision process. The authors apologize for any confusion this may have caused.

*Correspondence: jkline@medicine.bsd.uchicago.edu.



Figure 2.

Cancer cell K^b expression is required for optimal activation of K^b-restricted antigen-specific TCR-tg $CD8^+$ T cells